Dermatitis News

The FDA approval of Amgen’s supplemental biologics license application for expanded use of Enbrel for treating pediatric patients with chronic plaque psoriasis was among recent developments reported on Healio.com/Dermatology.

The American Academy of Dermatology has announced that ContextMedia:Health has been selected as a patient education affinity partner.

A survey of physicians in the United States and Canada found that there is great variation in prescribing practices of systemic agents to treat atopic dermatitis, according to results published in the Journal of the American Academy of Dermatology.

The American Society of Dermatologic Surgery announced that Thomas E. Rohrer, MD, began his term as president of the society and the American Society for Dermatologic Surgery Association during the ASDS annual meeting in New Orleans.

Women with rosacea had a significantly higher risk for incident migraine compared with the general Danish population, according to study results recently published in the Journal of the American Academy of Dermatology.

Research finding that treatment with Xeljanz in adolescents with alopecia areata resulted in significant hair regrowth for the majority of the patients was among the most-read articles of the past week on Healio.com/Dermatology.

Research finding that experts frequently misdiagnosed melanoma-associated leukoderma as vitiligo in a blinded assessment was among the most-read articles of the past week on Healio.com/Dermatology.

Research finding that women who applied broad-spectrum photostable sunscreen to their face daily for a year showed improvement in the signs of existing photodamaged skin was among the most-read articles in October on Healio.com/Dermatology.

Research presented at the European Academy of Dermatology and Venereology Congress showing that Cosentyx was superior to placebo at 12 weeks for clearing moderate-to-severe scalp psoriasis was among recent developments reported on Healio.com/Dermatology.

Research finding that patients with moderate-to-severe psoriasis who were treated with Xeljanz saw improvements in health-related quality of life over 52 weeks, with rapid improvement in pruritus, as among the most-read articles of the past week on Healio.com/Dermatology.